Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 247-368-0 | CAS number: 25956-17-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated Dose Toxicity study : Oral:
The No Observed Adverse Effect Level (NOAEL) of the test chemical in the rat via oral route of exposure is considered to be 7300 mg/kg body weight in male and 8300 mg/kg body weight in female animals.
Repeated dose Inhalation toxicity
The short term inhalation study need not be conducted because exposure of humans via inhalation in production and/or use is not likely as based on the thorough and rigorous exposure. The estimated vapour pressure of test chemical at 25 deg C was observed to be at 1.67E-021 Pa. Hence, this endpoint was considered for waiver.
Repeated dose Dermal toxicity
The short term inhalation study need not be conducted because exposure of humans via inhalation in production and/or use is not likely as based on the thorough and rigorous exposure.The acute dermal LD50 of the test chemical can be considered to be >2000 mg/kgbw. Hence, this endpoint was considered for waiver.
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from publication
- Qualifier:
- according to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- Toxicity of test chemical was assessed in HaM/ICR (CD-1) mice in life time study.
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- mouse
- Strain:
- other: HaM/ICR (CD-1)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories
- Age at study initiation: 50 days old
- Weight at study initiation: No data
- Fasting period before study: No data
- Housing: Five mice were housed in each polycarbonate box cage. Heat-treated wood chips served as the bedding material.
- Diet (e.g. ad libitum): Purina Laboratory Chow ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: No data
DETAILS OF FOOD AND WATER QUALITY:
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20-21°C
- Humidity (%): 40-60%
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12-hr light/dark cycle
IN-LIFE DATES: From: To: - Route of administration:
- oral: feed
- Details on route of administration:
- Purina Laboratory Chow
- Vehicle:
- other: Purina Laboratory Chow
- Details on oral exposure:
- Fresh diets were prepared and presented weekly. The test material was incorporated into the basal diet using a Patterson- Kelley twin shell blender, and assays were performed to determine the homogeneity and stability of test chemical in the prepared diets.
- Duration of treatment / exposure:
- 104 weeks
- Frequency of treatment:
- 1 wk prior to breeding, throughout a 2- or 3-wk breeding period, and during the gestation and lactation periods. When the last litter reached 21 days of age, weanling mice were randomly selected to populate the F1 phase.
- Remarks:
- Males: 0.37, 1.39 or 5.19% (0, 507, 1877, 7422 mg/kg bw/day)
- Remarks:
- Females: 0.37, 1.39 or 5.19% (0, 577, 2043, 8304 mg/kg bw/day)
- No. of animals per sex per dose:
- 50 mice/sex/group
- Control animals:
- yes, concurrent vehicle
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Once daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: weekly (wk 0-10) and every 4 wk thereafter
BODY WEIGHT: Yes
- Time schedule for examinations: weekly (wk 0-10) biweekly (wk 11-26) and every 4 wk thereafter
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):Yes
- Time schedule for examinations: weekly (wk 0-10) and every 4 wk thereafter
FOOD EFFICIENCY: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Blood collected from the tail vein during the study, and from the
abdominal aorta at termination at wk 13, 26, 52 and termination
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: 5 mice/sex/group
- Parameters checked: haematocrit, haemoglobin, erythrocyte count, and total and differential leucocyte counts.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Blood collected from the tail vein during the study, and from the
abdominal aorta at termination at wk 52 and at termination
- Animals fasted: No data
- How many animals: 5 mice/sex/group
- Parameters checked: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, fasting glucose, total protein, serum calcium and total bilirubin.
URINALYSIS: Yes
- Time schedule for collection of urine: Urine samples were obtained by housing mice overnight in metabolism cages (5/cage) at wk 52 and at termination.
- Metabolism cages used for collection of urine: Yes
- Animals fasted: No data
- Parameters checked: specific gravity, pH, glucose, ketones, total protein, bilirubin and sediment.
NEUROBEHAVIOURAL EXAMINATION: No data
OTHER: - Sacrifice and pathology:
- Sacrifice and pathology
GROSS PATHOLOGY: Yes
Gross autopsies were conducted on all mice that died spontaneously, were killed in a moribund condition, or were killed at termination. Mice were killed by exsanguination under sodium pentobarbital. Absolute and relative organ weights were determined for the heart, liver, spleen, kidneys, testes with epididymides, thyroid and adrenal glands.
HISTOPATHOLOGY: Yes
Mice killed at 42 wk for histopathological evaluation and complete histology was conducted on all mice from all groups - Statistics:
- Gain in group mean body weight and total food consumption, group mean body weight at termination, and absolute and relative organ weights were analysed by the methods of Bartlett (1937), Scheffe (1953) and Snedecor and Cochran (1967a). Survival data were analysed by the methods of Sachs (1959) and Snedecor and Cochran (1967b).
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no compound-related effects on survival.
Localized alopecia, laboured respiration, coloured hair coat, lacrimation and thinness were noted in similar incidences among control and treated mice. - Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no consistent statistically significant compound-related effects on mean body weights or survival.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food consumption decreased among the mid- and high-dose males for wk 50-104. There were no consistent statistically significant compound-related effects on mean food consumption.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- Few of the haematological parameters differed significantly between control and treated mice, and none of the differences was compound related.
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Few of the Clinical chemistry parameters differed significantly between control and treated mice, and none of the differences was compound related.
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- Few of the Urinanalysis parameters differed significantly between control and treated mice, and none of the differences was compound related.
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- No significant compound related gross changes, including changes in organ weights, were noted in mice that died on test or were killed during the study or at termination.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No significant compound related gross changes, including changes in organ weights, were noted in mice that died on test or were killed during the study or at termination.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- The mean thyroid weights in the high-dose males and females were 0.0133 and 0.0099 g, respectively, compared with 0.00879 and 0.0078 g in controls (P < 0.05). The respective thyroid/body-weight ratios were 3.51 and 3.23 compared with 2.26 and 2.36 in controls (P ~< 0.05). The significance of these findings
is unclear; there was no histopathology, they were apparently not dose-dependent but were observed at the highest level only and appear to be species-specific. The appearance of lymphocytic lymphoma occurred in study A earlier among treated groups than among controls. Lymphomas were observed in one low-dose male, one mid-dose female and two males and females from the high-dose group between wk 31 and 37. Lymphomas were not observed among controls until wk 85 and 70 for males and females, respectively - Other effects:
- not specified
- Dose descriptor:
- NOAEL
- Effect level:
- 7 300 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- Remarks on result:
- other: No adverse effect observed
- Dose descriptor:
- NOAEL
- Effect level:
- 8 300 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- body weight and weight gain
- clinical biochemistry
- clinical signs
- food consumption and compound intake
- gross pathology
- haematology
- histopathology: non-neoplastic
- mortality
- organ weights and organ / body weight ratios
- Remarks on result:
- other: No adverse effect observed
- Critical effects observed:
- no
- System:
- other: not specified
- Organ:
- not specified
- Conclusions:
- The NOAEL value of test chemical to Male and female HaM/ICR (CD-1) mice in life time study was observed at dose concentration of 7300 and 8300 mg/kg bw/day respectively.
- Executive summary:
Toxicity of test chemical was assessed in HaM/ICR (CD-1) mice in life time study. 50 CD1 mice per sex per dose group were fed test chemical in diet at dose concentration of Males: 0.37, 1.39 or 5.19% (0, 507, 1877, 7422 mg/kg bw/day), Females: 0.37, 1.39 or 5.19% (0, 577, 2043, 8304 mg/kg bw/day), for1 wk prior to breeding, throughout a 2- or 3-wk breeding period, and during the gestation and lactation periods. When the last litter reached 21 days of age, weanling mice were randomly selected to populate the F1 phase. No significant compound related adverse effect were observed on mortality, clinical signs, body weight, food consumption, hematology, clinical chemistry,gross and histopathology. Hence no-observable-adverse effect level in these studies was 5.19%; approximately 7300 and 8300 mg/kg body weight/day for male and female mice, respectively.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 7 300 mg/kg bw/day
- Study duration:
- chronic
- Species:
- mouse
- Quality of whole database:
- Data is Klimish 2 and from publication
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: inhalation, other
- Data waiving:
- other justification
- Justification for data waiving:
- a short-term toxicity study does not need to be conducted because exposure of humans via inhalation in production and/or use is not likely as based on the provided thorough and rigorous exposure assessment
Reference
Endpoint conclusion
- Quality of whole database:
- Waiver
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: dermal, other
- Data waiving:
- other justification
- Justification for data waiving:
- a short-term toxicity study does not need to be conducted because exposure of humans via the dermal route in production and/or use is not likely as based on the provided thorough and rigorous exposure assessment
Reference
Endpoint conclusion
- Quality of whole database:
- Waiver
Additional information
Repeated dose Oral toxicity:
Various studies have been reviewed to determine the toxicity of the test chemical when dosed repeatedly via oral route to living organisms. These include in vivo experimental studies performed on rats and mice:
Toxicity of test chemical was assessed in HaM/ICR (CD-1) mice in life time study. 50 CD1 mice per sex per dose group were fed test chemical in diet at dose concentration of Males: 0.37, 1.39 or 5.19% (0, 507, 1877, 7422 mg/kg bw/day), Females: 0.37, 1.39 or 5.19% (0, 577, 2043, 8304 mg/kg bw/day), for1 wk prior to breeding, throughout a 2- or 3-wk breeding period, and during the gestation and lactation periods. When the last litter reached 21 days of age, weanling mice were randomly selected to populate the F1 phase. No significant compound related adverse effect were observed on mortality, clinical signs, body weight, food consumption, hematology, clinical chemistry,gross and histopathology. Hence no-observable-adverse effect level in these studies was 5.19%; approximately 7300 and 8300 mg/kg body weight/day for male and female mice, respectively.
In another study, Toxicity of test chemical was assessed in CD-1 outbreed mice in life time study. 50 CD1 mice per sex per dose group were fed test chemical in diet at dose concentration of Males: 0.37, 1.39 or 5.19% (0, 507, 1877, 7422 mg/kg bw/day), Females: 0.37, 1.39 or 5.19% (0, 577, 2043, 8304 mg/kg bw/day), for1 wk prior to breeding, throughout a 2- or 3-wk breeding period, and during the gestation and lactation periods. When the last litter reached 21 days of age, weanling mice were randomly selected to populate the F1 phase. No significant compound related adverse effects were observed on mortality, clinical signs, body weight, food consumption, hematology, clinical chemistry, gross and histopathology. Hence no-observable-adverse effect level in these studies was 5.19%; approximately 7300 and 8300 mg/kg body weight/day for male and female mice, respectively.
In a similar study, Toxicity of test chemical was assessed in Sprague Dawley rats in life time study. 30 Sprague Dawley rats per sex per dose group were fed test chemical in diet at dose concentration of Males: 0.37, 1.39 or 5.19% (0, 180, 701,2829 mg/kg bw/day), Females: 0.37, 1.39 or 5.19% (0, 228, 901, 3604 mg/kg bw/day), 1 wk before mating, throughout the 3-wk breeding period, and during the gestation and lactation periods .No significant compound related adverse effect were observed on mortality, clinical signs, body weight (except for a reduction in body weight in high-dose females at the end of the study), food consumption, hematology, clinical chemistry, gross and .The no adverse-effect levels in this study were 5.19% (2829 mg/kg/day) for male rats, and 1.39% (901 mg/kg/day) for female rats.
Based on the available results, the test chemical can be considered to be non-toxic to living organisms when dosed repeatedly via oral route. The No Observed Adverse Effect Level can be considered to be >1000 mg/kgbw/day. Comparing the above annotations with the criteria of CLP Regulation, the test chemical can be classified under the category “Not Classified”
Repeated dose Inhalation toxicity
The short term inhalation study need not be conducted because exposure of humans via inhalation in production and/or use is not likely as based on the thorough and rigorous exposure. The estimated vapour pressure of test chemical at 25 deg C was observed to be at 1.67E-021 Pa. Hence, this endpoint was considered for waiver.
Repeated dose Dermal toxicity
The short term inhalation study need not be conducted because exposure of humans via inhalation in production and/or use is not likely as based on the thorough and rigorous exposure.The acute dermal LD50 of the test chemical can be considered to be >2000 mg/kgbw. Hence, this endpoint was considered for waiver.
Justification for classification or non-classification
Available studies indicate that the test chemical is likely to be non-toxic when exposed via oral, dermal or inhalation route to various living organisms.
According tocriteria of CLP Regulation, the test chemical can be classified under the category “Not Classified”.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.